

Corrigendum

Propranolol inhibits cavernous vascular malformations by β_1 adrenergic receptor antagonism in animal models

Wenqing Li, Robert Shenkar, Mathew R. Detter, Thomas Moore, Christian Benavides, Rhonda Lightle, Romuald Girard, Nicholas Hobson, Ying Cao, Yan Li, Erin Griffin, Carol Gallione, Joseph M. Zabramski, Mark H. Ginsberg, Douglas A. Marchuk, and Issam A. Awad

Original citation: *J Clin Invest.* 2021;131(3):e144893. <https://doi.org/10.1172/JCI144893>.

Citation for this corrigendum: *J Clin Invest.* 2021;131(19):e154909. <https://doi.org/10.1172/JCI154909>.

Following the publication of this article, the authors became aware that an incorrect panel was used for Figure 3B. The correct panel for Figure 3B is below, showing the change in heart rate when mice were challenged with isoproterenol in a murine model of cerebral cavernous malformation treated with vehicle or propranolol. The Figure 3 legend is amended as follows: $***P < 0.001$, by 2-way repeated-measures ANOVA with a post hoc Tukey's honest significant difference test. The authors have stated that this corrected panel does not affect the results or conclusions of the article.

The authors regret the error.

